Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

GreenLight Biosciences Holdings GRNAW NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
21/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

GreenLight Biosciences Holdings (GRNAW) is a Biotechnology company in the Healthcare sector, currently trading at $0.02. It has a SharesGrow Score of 20/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $6M, -84%/yr average growth. Net income is $167M (loss), growing at -81.5%/yr. Net profit margin is -2616.8% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $80M against $48M equity (Debt-to-Equity (D/E) ratio 1.67, leveraged). Current ratio is 2.01 (strong liquidity). Debt-to-assets is 54.2%. Total assets: $149M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 46/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

GRNAW SharesGrow Score Overview

26/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GRNAW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
GRNAW: -84%/yr revenue is, -81.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet GRNAW: Debt-to-Equity (D/E) ratio 1.67 (leveraged), Current ratio is 2.01 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
GRNAW: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
GRNAW: Net profit margin is -2616.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.022-0.022
Volume550
Beta (1Y)0.00
Share Statistics
EPS (TTM)-1.27
Shares Outstanding$131.98M
Employees280
Financial Highlights & Ratios
Revenue (TTM)$6.38M
Gross Profit$6.38M
EBITDA$-153.99M
Net Income$-167.06M
Operating Income$-163.92M
Total Cash$68.1M
Total Debt$80.48M
Net Debt$12.39M
Total Assets$148.6M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD

Price Chart

Track all markets on TradingView
GRNAW
GreenLight Biosciences Holdings ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology

People Also View

EQRXW
EQRXW
EQRx, Inc.
$0.05
+0.00%
 DRTSW
DRTSW
Alpha Tau Medical Ltd.
$0.94
+0.00%
 GRNA
GRNA
GreenLight Biosciences Holdings
$0.30
-0.03%
 REVBW
REVBW
Revelation Biosciences, Inc.
$0.01
-7.53%
 DCFCW
DCFCW
Tritium DCFC Limited
$0.02
+0.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message